Exagen beats Q1 revenue estimates, reaffirms 2026 guidance

Exagen

11/05/2026 13:09

Overview

US autoimmune testing provider's Q1 revenue grew 12% yr/yr, beating analyst expectations

Adjusted EBITDA loss for Q1 improved 14% yr/yr

Company reaffirmed full-year 2026 revenue guidance of $70 mln to $73 mln

Outlook

Exagen continues to expect full-year 2026 revenue of $70 mln to $73 mln

Result Drivers

TEST VOLUME GROWTH - AVISE CTD test volume rose 10% compared to Q1 2025

HIGHER AVERAGE SELLING PRICE - AVISE CTD trailing-twelve-month ASP increased 6% year-over-year to $444 per test

REVENUE CYCLE MANAGEMENT - CEO cited disciplined execution and effective revenue cycle management as supporting Q1 results

Company press release: ID:nGNX7YJRSm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$17.31 mln
$16.41 mln (7 Analysts)
Q1 Net Income
-$3.97 mln
Q1 Operating Expenses
$13.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Exagen Inc is $8.50, about 188.1% above its May 8 closing price of $2.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)